Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 11;7(1):41.
doi: 10.3390/jof7010041.

Recent Advances and Novel Approaches in Laboratory-Based Diagnostic Mycology

Affiliations
Review

Recent Advances and Novel Approaches in Laboratory-Based Diagnostic Mycology

Lewis P White et al. J Fungi (Basel). .

Abstract

What was once just culture and microscopy the field of diagnostic mycology has significantly advanced in recent years and continues to incorporate novel assays and strategies to meet the changes in clinical demand. The emergence of widespread resistance to antifungal therapy has led to the development of a range of molecular tests that target mutations associated with phenotypic resistance, to complement classical susceptibility testing and initial applications of next-generation sequencing are being described. Lateral flow assays provide rapid results, with simplicity allowing the test to be performed outside specialist centres, potentially as point-of-care tests. Mycology has responded positively to an ever-diversifying patient population by rapidly identifying risk and developing diagnostic strategies to improve patient management. Nowadays, the diagnostic repertoire of the mycology laboratory employs classical, molecular and serological tests and should be keen to embrace diagnostic advancements that can improve diagnosis in this notoriously difficult field.

Keywords: advances in molecular diagnostics; advances in serology; mycology; next-generation sequencing; novel targets and applications.

PubMed Disclaimer

Conflict of interest statement

Performed diagnostic evaluations and received meeting sponsorship from Bruker, Dynamiker, and Launch Diagnostics; Performed diagnostic evaluations for Associates of Cape Cod. Speakers fees, expert advice fees and meeting sponsorship from Gilead; and speaker and expert advice fees from F2G and speaker fees MSD and Pfizer. Is a founding member of the European Aspergillus PCR Initiative. J.S. Price declares no conflict of interest.

Similar articles

Cited by

References

    1. Nedel W.L., Kontoyiannis D.P., Pasqualotto A.C. Aspergillosis in patients treated with monoclonal antibodies. Rev. Iberoam. Micol. 2009;26:175–183. doi: 10.1016/j.riam.2009.04.001. - DOI - PubMed
    1. White L., Dhillon R., Cordey A., Hughes H., Faggian F., Soni S., Pandey M., Whitaker H., May A., Morgan M., et al. A National Strategy to Diagnose COVID-19 Associated Invasive Fungal Disease in the ICU. Clin. Infect. Dis. 2020:ciaa1298. doi: 10.1093/cid/ciaa1298. - DOI - PMC - PubMed
    1. Arastehfar A., Carvalho A., Nguyen M.H., Hedayati M.T., Netea M.G., Perlin D.S., Hoenigl M. COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions? J. Fungi. 2020;6:E211. doi: 10.3390/jof6040211. - DOI - PMC - PubMed
    1. Armstrong-James D., Youngs J., Bicanic T., Abdolrasouli A., Denning D.W., Johnson E., Mehra V., Pagliuca T., Patel B., Rhodes J., et al. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. Eur. Respir. J. 2020;56:2002554. doi: 10.1183/13993003.02554-2020. - DOI - PMC - PubMed
    1. Loughlin L., Hellyer T.P., White P.L., McAuley D.F., Conway Morris A., Posso R.B., Richardson M.D., Denning D.W., Simpson A.J., McMullan R. Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs. Am. J. Respir. Crit. Care Med. 2020;202:1125–1132. doi: 10.1164/rccm.202002-0355OC. - DOI - PMC - PubMed

LinkOut - more resources